BIIB vs REFR · P/E 21, rev $9.89B vs rev $222.7K
Biogen Inc (BIIB) versus Research Frontiers Incorporated (REFR) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Research Frontiers Incorporated (REFR) is a electronic components company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported REFR revenue for 2026-06-30 was $222.7K. Net income was -$1.2M. Revenue was up 63.3% from 2026-03-31 to 2026-06-30. REFR currently screens at market cap $22.4M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. REFR currently screens at market cap $22.4M.
Not investment advice. Open the BIIB and REFR stock pages for the full models.
Not investment advice.